Compare Nasdaq Inc (NDAQ) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq Inc vs Recursion Pharmaceuticals Inc — how do they compare? Nasdaq Inc trades at $92.85 (market cap $51.63B), while Recursion Pharmaceuticals Inc trades at $4.17 (market cap $2.14B). The key difference: Nasdaq Inc is far larger — about 24.1× Recursion Pharmaceuticals Inc's market cap, and Nasdaq Inc pays a 1.26% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq Inc for 125 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| NDAQ | RXRX | |
|---|---|---|
Market Cap | $51.63B | $2.14B |
Volume | 2,668,175 | 30,789,535 |
Sector | Financials | Health |
52-Week High | $100.98 | $6.79 |
52-Week Low | $76.85 | $2.84 |
Typical Hold Time | 125 Days | 22 Days |
Enterprise Value | $58.09B | $1.66B |
Dividend Yield | 1.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nasdaq Inc. (NDAQ) trades at $91.93, down 0.37% on the day, with strong fundamentals including 2025 revenue of $8.26B and net income of $1.79B. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $1.02 EPS. Technical indicators show a bearish overall signal despite bullish moving averages, with key support at $90 and resistance at $92-94.
NDAQ presents a compelling investment case with 61% analyst buy ratings and a $110.43 consensus price target, representing 20% upside. Strong profitability metrics (22.5% net margin, 16.5% ROE) and growing Financial Technology business offset technical weakness. Risks include market volatility exposure and competitive pressures in exchange services.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
